Squamous Cell Carcinoma of Head and Neck: all 1,711 studies

Page 6 of 18. Open to participants first (544), then studies with results posted, then the rest; newest registration first within each.

• Non Elective Vulnerable Elderly RadiotherapyRecruitingNCT04832555Not applicable
• Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCCRecruitingNCT04826679Phase 2
• Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)RecruitingNCT04807140Phase 2
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067RecruitingNCT04787042Phase 1/2
• Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsRecruitingNCT04777994Phase 1
• Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck CancerRecruitingNCT04754321Phase 1
• Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck CancersRecruitingNCT04747054Phase 3
• A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck CancerRecruitingNCT04722523Phase 1
• Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCCRecruitingNCT04688528Not applicable
• Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCCRecruitingNCT04681469Phase 2
• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT04671667Phase 2
• A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and NeckRecruitingNCT04597476Phase 2
• Specific Methylation Profiles in HNSCCRecruitingNCT04567056
• Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCCRecruitingNCT04564989
• Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue NeoplasiaRecruitingNCT04534127Not applicable
• Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck CancerRecruitingNCT04528420Not applicable
• Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal CancerRecruitingNCT04444869Phase 2
• Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsRecruitingNCT04429542Phase 1
• A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingNCT04389632Phase 1
• Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell CancerRecruitingNCT04375384Phase 2
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT04370587Phase 1/2
• Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity CancerRecruitingNCT04333537Phase 2/3
• Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell CarcinomaRecruitingNCT04220749Phase 2
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)RecruitingNCT04198766Phase 1/2
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsRecruitingNCT04119024Phase 1
• Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor MalignanciesRecruitingNCT04114136Phase 2
• Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.RecruitingNCT03889899Not applicable
• Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-ImagingNot yet recruitingNCT03865277Phase 2
• Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And NeckRecruitingNCT03830385Phase 2
• Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT03815903Phase 3
• Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsRecruitingNCT03740256Phase 1
• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaRecruitingNCT03556228Phase 1/2
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsRecruitingNCT03526835Phase 1/2
• Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell CarcinomaRecruitingNCT03406247Phase 2
• De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell CarcinomasRecruitingNCT03396718Not applicable
• Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal CancerRecruitingNCT03114462Phase 1
• Prognostic Impact of Tumor Growth Velocity in Head and Neck Squamous Cell Carcinoma Treated by Radio(Chemo)TherapyNot yet recruitingNCT02990936
• A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.RecruitingNCT02743832Not applicable
• Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryRecruitingNCT02734537Phase 2
• Patient-derived Xenograft Models of Tumor From Patients With Head and Neck CancerRecruitingNCT02572778
• Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 StageRecruitingNCT02290145Phase 2
• Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck PatientsRecruitingNCT02139020
• Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and NeckRecruitingNCT01473784Not applicable
• Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy ParticipantsRecruitingNCT00898638
• Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell CarcinomaTerminatedNCT06046482Phase 2Results posted
• Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal CancerActive, not recruitingNCT05996523Phase 2Results posted
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell CarcinomaCompletedNCT05909904Phase 2Results posted
• Activity and Safety of Danvatirsen and Pembrolizumab in HNSCCTerminatedNCT05814666Phase 2Results posted
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursTerminatedNCT05714553Phase 1/2Results posted
• A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsTerminatedNCT05551117Phase 2Results posted
• A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China ExtensionCompletedNCT05523323Phase 3Results posted
• A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)CompletedNCT05459129Phase 1/2Results posted
• A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)CompletedNCT05323656Phase 2Results posted
• A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During SurgeryTerminatedNCT05316688Phase 1/2Results posted
• Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer PatientsCompletedNCT05294900Phase 2Results posted
• Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT05287113Phase 2Results posted
• Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck CancersCompletedNCT05120947Not applicableResults posted
• IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCCompletedNCT05077709Phase 2Results posted
• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)TerminatedNCT05061420Phase 2Results posted
• Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCCCompletedNCT05057247Phase 2Results posted
• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)CompletedNCT05007106Phase 2Results posted
• Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell CarcinomaTerminatedNCT04936841Phase 2Results posted
• A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerTerminatedNCT04916002Phase 2Results posted
• Neoadjuvant Imiquimod Immunotherapy for Oral CancerCompletedNCT04883645Early Phase 1Results posted
• A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of CancersCompletedNCT04879849Phase 1Results posted
• Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell CarcinomaTerminatedNCT04854499Phase 2Results posted
• A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic CancerTerminatedNCT04844073Phase 1/2Results posted
• Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer PatientsCompletedNCT04752384Phase 2Results posted
• Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive DiseaseTerminatedNCT04685499Phase 2Results posted
• A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and NeckCompletedNCT04665843Phase 2Results posted
• Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell CarcinomaCompletedNCT04649476Phase 2Results posted
• Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerTerminatedNCT04634825Phase 2Results posted
• CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT04633278Phase 2Results posted
• Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid TumorsTerminatedNCT04628780Phase 1Results posted
• Study of NKTR 255 in Combination With Cetuximab in Solid TumorsCompletedNCT04616196Phase 1/2Results posted
• Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerActive, not recruitingNCT04590963Phase 3Results posted
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive, not recruitingNCT04576091Phase 1Results posted
• Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerCompletedNCT04555837Phase 1/2Results posted
• Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With CisplatinCompletedNCT04541355Phase 2Results posted
• Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or SkinTerminatedNCT04502888Phase 1Results posted
• A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)CompletedNCT04489888Phase 4Results posted
• A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)TerminatedNCT04459715Phase 3Results posted
• Quad Shot Radiotherapy in Combination With Immune Checkpoint InhibitionCompletedNCT04454489Phase 2Results posted
• A Study of NM21-1480 in Adult Patients With Advanced Solid TumorsTerminatedNCT04442126Phase 1/2Results posted
• Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT04428333Phase 3Results posted
• Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)CompletedNCT04428151Phase 2Results posted
• A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid TumorsTerminatedNCT04424641Phase 1/2Results posted
• Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer PatientsActive, not recruitingNCT04414540Phase 2Results posted
• HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell CarcinomaCompletedNCT04369937Phase 2Results posted
• Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyCompletedNCT04326257Phase 2Results posted
• Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)CompletedNCT04282109Phase 2Results posted
• Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCCTerminatedNCT04242173Phase 2Results posted
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsTerminatedNCT04234113Phase 1Results posted
• Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)CompletedNCT04220866Phase 2Results posted
• Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell CancerTerminatedNCT04220775Phase 1/2Results posted
• A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)CompletedNCT04199104Phase 3Results posted
• A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck CancerTerminatedNCT04193293Phase 1/2Results posted
• Using MASL to Combat Oral CancerCompletedNCT04188665Early Phase 1Results posted
• Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)TerminatedNCT04169074Phase 2Results posted
• A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck CancerCompletedNCT04144517Phase 2Results posted

← Squamous Cell Carcinoma of Head and Neck overview